MoonLake Immunotherapeutics (MLTX) grants CSO 520,342 options

Rhea-AI Filing Summary

MoonLake Immunotherapeutics reported an equity award to its Chief Scientific Officer, Kristian Reich, on a Form 4. On January 7, 2026, he received a stock option covering 520,342 Class A ordinary shares at an exercise price of $11.29 per share.

The option was granted for no cash cost at grant and is held directly by the reporting person. It vests in four equal annual installments on January 7, 2027, 2028, 2029 and 2030, and each vesting date is conditioned on his continued service to the company. After the transaction, he beneficially owned 520,342 derivative securities through this option.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Reich Kristian

(Last) (First) (Middle)

C/O MOONLAKE IMMUNOTHERAPEUTICS

DORFSTRASSE 29

(Street)

ZUG V8 6300

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MoonLake Immunotherapeutics [ MLTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$11.29	01/07/2026		A		520,342		(1)	01/07/2036	Class A ordinary shares, par value $0.0001 per share	520,342	$0	520,342	D

Explanation of Responses:

1. This option represents a right to purchase a total of 520,342 of the Issuer's Class A ordinary shares, vesting in four equal annual installments on January 7, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.

	/s/ Matthias Bodenstedt, Attorney-in-fact for Kristian Reich	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did MoonLake Immunotherapeutics (MLTX) disclose?

The company disclosed on a Form 4 that Chief Scientific Officer Kristian Reich was granted a stock option for 520,342 Class A ordinary shares on January 7, 2026.

What is the exercise price of the stock option granted to MoonLake CSO Kristian Reich?

The stock option granted to Chief Scientific Officer Kristian Reich has an exercise price of $11.29 per share for the underlying Class A ordinary shares.

How many MoonLake Immunotherapeutics shares underlie the reported stock option?

The reported stock option represents the right to purchase a total of 520,342 of MoonLake Immunotherapeutics’ Class A ordinary shares.

What is the vesting schedule for Kristian Reich’s MoonLake stock option?

The option vests in four equal annual installments on January 7, 2027, 2028, 2029 and 2030, subject to his continued service to MoonLake Immunotherapeutics through each applicable vesting date.

Did this Form 4 report any sales of MoonLake Immunotherapeutics shares?

No sales of Class A ordinary shares were reported. The Form 4 reports the grant of a stock option (a derivative security) covering 520,342 shares held directly by the reporting person.

How many derivative securities does the MoonLake CSO beneficially own after this transaction?

Following the reported grant, Chief Scientific Officer Kristian Reich beneficially owns 520,342 derivative securities through this stock option.